Report
Malaria vaccine GRADE Evidence table
Malaria Vaccine GRADE Evidence table, SAGE Yellow Book - September 2023 https://terrance.who.int/mediacentre/data/sage/SAGE_eYB_Sept2023.pdf
Prepared by Cochrane Response for review by the SAGE/MPAG Working Group on Malaria Vaccines
Question: Should a malaria vaccine be provided to reduce malaria disease burden in children ≥ 5 months of age living in regions with endemic malaria transmission?
Population: Children ≥ 5 months of age
Intervention: Malaria vaccination (RTS,S/AS01 and R21/Matrix-M)
Comparison: Malaria prevention interventions currently in place without malaria vaccination
Setting: regions with endemic low, moderate, or high malaria transmission
Languages
- English
Publication year
2023
Type
Report
Categories
- Programme management
Topic references
Malaria-evidence
| Title | Author | Year | Type | Language |
|---|---|---|---|---|
| Full evidence report on the R21/Matrix-M malaria vaccine | World Health Organization (WHO) | 2023 | Report | English |
| Full evidence report on the RTS,S/AS01 malaria vaccine | World Health Organization (WHO) | 2021 | Report | English |
| Malaria Vaccine Evidence-to-Recommendations Framework: R21/Matrix-M | 2023 | Report | English | |
| Malaria vaccine GRADE Evidence table | 2023 | Report | English |
